330 related articles for article (PubMed ID: 24952202)
1. Biomarkers in major depressive disorder: the role of mass spectrometry.
Woods AG; Iosifescu DV; Darie CC
Adv Exp Med Biol; 2014; 806():545-60. PubMed ID: 24952202
[TBL] [Abstract][Full Text] [Related]
2. Protein Biomarkers in Major Depressive Disorder: An Update.
Woods AG; Wormwood KL; Iosifescu DV; Murrough J; Darie CC
Adv Exp Med Biol; 2019; 1140():585-600. PubMed ID: 31347073
[TBL] [Abstract][Full Text] [Related]
3. Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders.
Preece RL; Han SYS; Bahn S
Expert Rev Proteomics; 2018 Apr; 15(4):325-340. PubMed ID: 29466886
[TBL] [Abstract][Full Text] [Related]
4. Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies.
Al Shweiki MR; Oeckl P; Steinacker P; Hengerer B; Schönfeldt-Lecuona C; Otto M
Expert Rev Proteomics; 2017 Jun; 14(6):499-514. PubMed ID: 28562112
[TBL] [Abstract][Full Text] [Related]
5. Distinct proteomic profiles in post-mortem pituitary glands from bipolar disorder and major depressive disorder patients.
Stelzhammer V; Alsaif M; Chan MK; Rahmoune H; Steeb H; Guest PC; Bahn S
J Psychiatr Res; 2015 Jan; 60():40-8. PubMed ID: 25455508
[TBL] [Abstract][Full Text] [Related]
6. Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis.
Ren J; Zhao G; Sun X; Liu H; Jiang P; Chen J; Wu Z; Peng D; Fang Y; Zhang C
Psychoneuroendocrinology; 2017 Dec; 86():17-24. PubMed ID: 28910601
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of argininosuccinate synthase as a candidate urinary biomarker for major depressive disorder.
Wu D; Peng Y; Zhou J; Yang YT; Rao CL; Bai SJ; Zhou XY; Chen J; Liao L; Liang ZH; Yang DY; Xie P
Clin Chim Acta; 2015 Dec; 451(Pt B):142-8. PubMed ID: 26394130
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometry-based proteomic quest for diabetes biomarkers.
Shao S; Guo T; Aebersold R
Biochim Biophys Acta; 2015 Jun; 1854(6):519-27. PubMed ID: 25556002
[TBL] [Abstract][Full Text] [Related]
9. Plasma lipidomics reveals potential lipid markers of major depressive disorder.
Liu X; Li J; Zheng P; Zhao X; Zhou C; Hu C; Hou X; Wang H; Xie P; Xu G
Anal Bioanal Chem; 2016 Sep; 408(23):6497-507. PubMed ID: 27457104
[TBL] [Abstract][Full Text] [Related]
10. Discovery of serum protein biomarkers in drug-free patients with major depressive disorder.
Lee MY; Kim EY; Kim SH; Cho KC; Ha K; Kim KP; Ahn YM
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():60-8. PubMed ID: 27105922
[TBL] [Abstract][Full Text] [Related]
11. Serum proteomic analysis of major depressive disorder patients and their remission status: Novel biomarker set of zinc-alpha-2-glycoprotein and keratin type II cytoskeletal 1.
Choi H; Mun S; Joo EJ; Lee KY; Kang HG; Lee J
Int J Biol Macromol; 2021 Jul; 183():2001-2008. PubMed ID: 34052271
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of major depressive disorder by combining multimodal information from heart rate dynamics and serum proteomics using machine-learning algorithm.
Kim EY; Lee MY; Kim SH; Ha K; Kim KP; Ahn YM
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jun; 76():65-71. PubMed ID: 28223106
[TBL] [Abstract][Full Text] [Related]
13. Proteomics Approach for Biomarker Research in Major Depression: Antidepressant Effects.
Huang TL; Lo LH
Curr Drug Metab; 2018; 19(6):502-512. PubMed ID: 29623831
[TBL] [Abstract][Full Text] [Related]
14. Toward an integrated pipeline for protein biomarker development.
Drabovich AP; Martínez-Morillo E; Diamandis EP
Biochim Biophys Acta; 2015 Jun; 1854(6):677-86. PubMed ID: 25218201
[TBL] [Abstract][Full Text] [Related]
15. Serum proteomic profiling of major depressive disorder.
Bot M; Chan MK; Jansen R; Lamers F; Vogelzangs N; Steiner J; Leweke FM; Rothermundt M; Cooper J; Bahn S; Penninx BW
Transl Psychiatry; 2015 Jul; 5(7):e599. PubMed ID: 26171980
[TBL] [Abstract][Full Text] [Related]
16. Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research.
Liu M; Ma W; He Y; Sun Z; Yang J
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959849
[TBL] [Abstract][Full Text] [Related]
17. Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses.
Jentsch MC; Van Buel EM; Bosker FJ; Gladkevich AV; Klein HC; Oude Voshaar RC; Ruhé EG; Eisel UL; Schoevers RA
Biomark Med; 2015; 9(3):277-97. PubMed ID: 25731213
[TBL] [Abstract][Full Text] [Related]
18. Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry.
Liu X; Zheng P; Zhao X; Zhang Y; Hu C; Li J; Zhao J; Zhou J; Xie P; Xu G
J Proteome Res; 2015 May; 14(5):2322-30. PubMed ID: 25784130
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
Chiasserini D; van Weering JR; Piersma SR; Pham TV; Malekzadeh A; Teunissen CE; de Wit H; Jiménez CR
J Proteomics; 2014 Jun; 106():191-204. PubMed ID: 24769233
[TBL] [Abstract][Full Text] [Related]
20. Targeted mass spectrometry approaches for protein biomarker verification.
Meng Z; Veenstra TD
J Proteomics; 2011 Nov; 74(12):2650-9. PubMed ID: 21540133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
